AnaptysBio’s (NASDAQ:ANAB) lock-up period is set to expire on Tuesday, July 25th. AnaptysBio had issued 5,000,000 shares in its initial public offering on January 26th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.
A number of research analysts have recently weighed in on the company. Zacks Investment Research raised AnaptysBio from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Robert W. Baird started coverage on AnaptysBio in a research note on Monday, July 10th. They set an “outperform” rating and a $36.00 price objective for the company. Credit Suisse Group reissued an “outperform” rating and set a $34.00 price objective on shares of AnaptysBio in a research note on Tuesday, April 18th. Finally, Stifel Nicolaus lifted their price target on AnaptysBio from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, May 2nd. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $35.60.
ILLEGAL ACTIVITY NOTICE: “AnaptysBio, Inc.’s Lock-Up Period Set To Expire on July 25th (NASDAQ:ANAB)” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://stocknewstimes.com/2017/08/11/anaptysbio-inc-s-lock-up-period-will-end-tomorrow-nasdaqanab-updated-updated.html.
Shares of AnaptysBio (ANAB) opened at 21.48 on Friday. The stock has a 50 day moving average price of $24.87 and a 200-day moving average price of $24.48. AnaptysBio has a 1-year low of $15.17 and a 1-year high of $30.71. The company’s market cap is $435.38 million.
AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.75) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.18) by $0.57. Equities research analysts forecast that AnaptysBio will post ($2.48) earnings per share for the current year.
In other news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the firm’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total value of $901,924.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Holdings A/S Novo sold 491,294 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $21.12, for a total transaction of $10,376,129.28. Following the completion of the sale, the insider now owns 2,952,527 shares of the company’s stock, valued at approximately $62,357,370.24. The disclosure for this sale can be found here. Insiders sold a total of 599,040 shares of company stock worth $12,926,210 over the last ninety days.
Hedge funds have recently made changes to their positions in the stock. Frazier Management LLC acquired a new position in shares of AnaptysBio during the first quarter worth about $102,354,000. Perceptive Advisors LLC acquired a new position in shares of AnaptysBio during the first quarter worth about $24,474,000. Hamilton Lane Advisors LLC acquired a new position in shares of AnaptysBio during the first quarter worth about $11,213,000. Marshall Wace North America L.P. acquired a new position in shares of AnaptysBio during the first quarter worth about $6,924,000. Finally, MARSHALL WACE ASIA Ltd acquired a new position in shares of AnaptysBio during the first quarter worth about $6,924,000. Hedge funds and other institutional investors own 72.79% of the company’s stock.
About AnaptysBio
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
